2719-96-2

Basic information

• Product Name: 3β-tosyloxyandrost-5-ene-17-one
• Synonyms: 3β-tosyloxyandrost-5-ene-17-one
• CAS NO: 2719-96-2
• Molecular Weight: 442.62
• Mol File: 2719-96-2.mol
• Article Data: 14

Chemical Properties

• CAS DataBase Reference: 3β-tosyloxyandrost-5-ene-17-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3β-tosyloxyandrost-5-ene-17-one(2719-96-2)
• EPA Substance Registry System: 3β-tosyloxyandrost-5-ene-17-one(2719-96-2)

Safety Data

• Hazardous Substances Data: 2719-96-2(Hazardous Substances Data)

Upstream product

• 979-02-2 16-dehydropregnenolone acetate 
• 23549-24-8 3β-acetoxy-20-hydroxyiminopregna-5,16-diene 
• 853-23-6 prasterone acetate 
• 53-43-0 dehydroepiandrosterone 
• 104-15-4 toluene-4-sulfonic acid 
• 98-59-9 p-toluenesulfonyl chloride 

Downstream Products

• 1237589-03-5 3β-cylcohexyloxy-5-androsten-17-one 
• 1224-07-3 3α,5α-cycloandrost-6-en-17-one 
• 897-01-8 (3S,8R,9S,10R,13S,14S)-3-Chloro-10,13-dimethyl-1,2,3,4,7,8,9,10,11,12,13,14,15,16-tetradecahydro-cyclopenta[a]phenanthren-17-one 
• 42151-23-5 (3S)-3-tert-butyldimethylsilyloxyandrost-5-en-17-one 
• 361-79-5 3β-fluoro-androst-5-en-17β-ol 
• 438-19-7 3beta-Fluoro-5alpha-androstan-17beta-ol 
• 76025-88-2 Acetic acid (2S,3R,5S,8R,9S,10R,13S,14S,17S)-17-acetoxy-10,13-dimethyl-6-oxo-3-(toluene-4-sulfonyloxy)-hexadecahydro-cyclopenta[a]phenanthren-2-yl ester 
• 76025-96-2 17β-acetoxy-3β-p-tolylsulphonyloxy-5α-androstan-6-one 
• 69389-41-9 3β-p-tolylsulphonyloxy-5α-androstan-6,17-dione 
• 2283-82-1 3α-hydroxy-androst-5-en-17-one 
• 5223-99-4 (3R,8R,9S,10R,13S,14S)-10,13-dimethyl-17-oxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-yl acetate 
• 1912-63-6 androsta-3,5-dien-17-one 
• 58691-91-1 6β-acetoxy-3α,5α-cycloandrostan-17-one 
• 28957-91-7 3β-Hydroxy-5α,6β-dichlorandrostan-17-on-p-toluolsulfonat 

Relevant articles and documents

Catalytic cyclometallation in steroid chemistry VI: Targeted synthesis of hybrid molecules based on steroids and tetradeca-5Z,9Z-diene-1,14-dicarboxylic acid and study of their antitumor activity

Hybrid molecules based on a number of steroids (cholesterol, pregnenolone, androsterone) and 1,14-tetradeca-5Z,9Z-dienedicarboxylic acid linked via mono- and diethylene glycol spacers were synthesized for the first time and studied for antitumor activity in vitro. The acid was prepared using catalytic cyclomagnesiation of oxygenated 1,2-dienes with Grignard reagent in the presence of Cp2TiCl2 as the key synthetic step. Using flow cytometry, the new molecules were shown for the first time to be efficient apoptosis inducers in the HeLa, Hek293, U937, Jurkat, and K562 cell cultures and to have dose-dependent effect on the S and G2 phases of the cell cycle.

Effect of additional double bonds on the mass spectrometric fragmentations of Δ4-3-keto steroids

-

CYP11B, CYP17, AND/OR CYP21 INHIBITORS

Provided herein are inhibitors of CYP11B, CYP17, and/or CYP21 enzymes of Formula (Z), (IX), (X), (XI), (XII), (XIII), (XIV), (XV), (XVI), or (XVII). Also described herein are pharmaceutical compositions that include at least one compound described herein and the use of a compound or pharmaceutical composition described herein to treat androgen-dependent diseases, disorders and conditions. Formula (Z)

AMINO DERIVATIVES OF ANDROSTANES AND ANDROSTENES AS MEDICAMENTS FOR CARDIOVASCULAR DISORDERS

Compounds of formula (I) wherein: the groups are as defined in the description, are useful for the preparation of medicaments for the treatment of cardiovascular disorders, in particular heart failure and hypertension. The compounds are inhibitors of the enzymatic activity of the Na+, K+-ATPase. Said compounds are used for the preparation of a medicament for the treatment of a disease caused by the hypertensive effects of endogenous ouabain, such as renal failure progression in autosomal dominant polycystic renal disease (ADPKD), preeclamptic hypertension and proteinuria and renal failure progression in patients with adducin polymorphisms.